The United States shares 60 million AstraZeneca vaccines with the rest of the world | right Now

The White House told the news agency Monday, that the United States wants to deliver some purchased AstraZeneca vaccines to other countries if the vaccine is approved by all authorities. AP. The country expects to be able to export up to 60 million doses in the coming months.

A month ago, US President Joe Biden had already decided to share four million vaccines with neighboring Mexico and Canada. AstraZeneca vaccine is already in use worldwide but has not yet been approved in the United States.

However, the state is reasonably insured of vaccines by the other three manufacturers, Pfizer, Moderna and Johnson & Johnson, so you might lose something. “Since we already have a robust batch of approved vaccines and AstraZeneca has not yet been approved in the United States, we will not need this vaccine in the coming months,” said Jeff Zentes, the White House Coronavirus Coordinator. Which is why we are looking for ways to help other countries with vaccines as well. “

According to Zients, ten million doses have now been completed, but are still awaiting approval by the FDA. 50 million doses are in various stages of production and can be delivered in May or June, depending on the decision of the FDA.

Vaccine shortages in many countries

The United States has yet to decide where the vaccines will go. Mexico and Canada have already asked the country to export more doses, but many other countries are also suffering from vaccine shortages due to AstraZeneca. The company has had to amend its promises several times in recent months and have delivered far less than they initially promised.

On Monday, the European Commission will take the company to court to denounce these delivery delays. AstraZeneca has so far provided only 30 million of the 120 million doses it promised to do this year and says it will deliver only 70 million of the 180 million doses it promised this year.

The British-Swedish pharmaceutical company responded with disappointment to Brussels’ decision on Monday. “After an unprecedented year of scientific discoveries, complex negotiations and industrialization issues, we aim to deliver about 50 million doses to European countries by the end of April. This is in line with our expectations,” the company stated on its website.

“AstraZeneca has always abided by its agreements with the European Union and will defend itself vigorously in court. We look forward to working constructively with the European Union to vaccinate as many people as possible.”